US · Healthcare · Medical Devices
EPS came in at 0.41 against a street estimate of 0.42 — a miss of 2.4%.
Analysts rate Iradimed Co a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $118.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.57% |
| Renaissance Technologies Corp | 3.45% |
| Copeland Capital Management, LLC | 3.06% |
| Vanguard Capital Management, LLC | 2.80% |
| Kayne Anderson Rudnick Investment Management LLC | 2.73% |
| Geode Capital Management, LLC | 2.24% |
| T. Rowe Price Investment Management,Inc. | 2.01% |
| Nine Ten Capital Management LLC | 2.01% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 IRADIMED CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6 months): $42,444 thousand (vs. $39,920 thousand in 2025) – up 6.3% • Reven | 2026-07-31 |
| Company announcement · Q3 2026 IRADIMED CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: IRADIMED CORPORATION (Ticker: IRMD, NASDAQ) • Report Date: July 31, 2026 for qua | 2026-07-31 |
| Shareholder vote results · Q2 2026 IRADIMED CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Stockholder Meeting held June 23, 2026 • Total votes cast for board directors: app | 2026-06-24 |
| Quarterly report · Q1 2026 IRADIMED CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $21.979 million vs. $19.511 million in Q1 2025 (+12.6% year-over-yea | 2026-05-01 |
| Results announced · Q2 2026 IRADIMED CORPORATION - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $22.0 million, up $2.5 million or 13% versus Q1 2025 ($19.5 mil | 2026-05-01 |
| Proxy statement · Q2 2026 IRADIMED CORPORATION PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 - Election of Five Directors: Vote to elect Roger Susi (President, C | 2026-04-30 |
| Annual report FY2025 IRADIMED CORPORATION - FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Fiscal year 2025 revenue: $83.8 million • Operating income: $26.1 m | 2026-03-06 |
| Results announced · Q1 2026 IRADIMED CORPORATION – EARNINGS SUMMARY HEADLINE NUMBERS • Q4 2025 Revenue: $22.7 million, up 17% YoY ($19.4 million in Q4 2024) • Q4 2025 GAAP Dilu | 2026-02-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Iradimed Co — free to start.
Google PlayApp StoreData updated 2026-09-18.